---
title: "IRADIMED CORPORATION Announces Fourth Quarter and Full Year 2024 Financial Results"
date: "2025-02-13 21:35:01"
summary: "IRADIMED CORPORATION, a leader in the development of innovative MRI-compatible medical devices, has released its financial results for the fourth quarter and full year ending December 31, 2024. The company, known for its non-magnetic intravenous infusion pump system and patient vital signs monitoring system, reported significant growth and operational achievements...."
categories:
  - "TradingView"
lang:
  - "en"
translations:
  - "en"
tags:
  - "TradingView"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

IRADIMED CORPORATION, a leader in the development of innovative MRI-compatible medical devices, has released its financial results for the fourth quarter and full year ending December 31, 2024. The company, known for its non-magnetic intravenous infusion pump system and patient vital signs monitoring system, reported significant growth and operational achievements.

**Financial Highlights**

For the fourth quarter of 2024, IRADIMED CORPORATION reported record revenue of $19.4 million, an 11% increase compared to the same period in 2023. The company also reported GAAP diluted EPS of $0.40 and non-GAAP diluted EPS of $0.44. For the full year of 2024, revenue reached $73.2 million, a 12% increase from 2023, with GAAP diluted EPS of $1.50 and non-GAAP diluted EPS of $1.66.

**Business and Operational Highlights**

The company's strong performance was driven by sustained demand for its IV infusion pumps, robust gross and operating margins, and a growing order backlog. Domestic sales accounted for 85% of total revenue in Q4 2024, up from 78% in Q4 2023. The gross profit margin for Q4 2024 was 76.1%, slightly down from 76.9% in Q4 2023. For the full year, the gross profit margin was 76.9%, up from 76.5% in 2023.

**Strategic Initiatives and Corporate Developments**

IRADIMED CORPORATION announced an increase in its regular quarterly cash dividend from $0.15 to $0.17 per share, payable on March 5, 2025. The company is also progressing with the construction of a new facility, expected to be completed by mid-2025, which will provide additional space to support future growth.

**Management's Perspective**

Roger Susi, President and CEO, expressed pride in the company's record-breaking quarter and sustained revenue growth. He highlighted the strong financial position and commitment to returning value to stockholders through increased dividends. Susi also mentioned the company's focus on delivering innovative solutions and driving long-term value for customers.

**Future Outlook**

For the full year 2025, IRADIMED CORPORATION expects to report revenue between $78.0 million and $82.0 million, GAAP diluted EPS of $1.55 to $1.65, and non-GAAP diluted EPS of $1.71 to $1.81. For Q1 2025, the company anticipates revenue between $19.2 million and $19.4 million, GAAP diluted EPS of $0.35 to $0.39, and non-GAAP diluted EPS of $0.39 to $0.43.

SEC Filing: [IRADIMED CORP [ IRMD ] - 8-K - Feb. 13, 2025](https://www.sec.gov/Archives/edgar/data/1325618/000155837025000907/irmd-20250213x8k.htm)

[TradingView](https://www.tradingview.com/news/tradingview:c8bcbfba7a655:0-iradimed-corporation-announces-fourth-quarter-and-full-year-2024-financial-results/)
